In $MRNA 24 hours, it rose 6.247%, and the price reached 155.63. Open interest is 8743, and the funding rate is zero.

I judge this to be a defensive rotation under expectations of geopolitical conflict. Capital is looking for biotech names beyond traditional energy and military-industrial stocks, and MRNA’s vaccine-platform narrative is being treated as an alternative safe haven amid heightened tensions.

The strongest counterargument is a de-escalation of the conflict; this kind of money will leave just as quickly, since it is purely event-driven. If risk appetite recovers, those who chase the move higher will pay the price.

At this point, trading options is a bet on the persistence of the event, and I do not believe this is driven by fundamentals.

Trading tag: #TradFi #链上美股 #MRNA

Where do you think this line of reasoning is most likely to be wrong?